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Abstract: Candida glabrata biofilms are recognized to have high resistance to antifungals. In order to 
understand the effect of mannans in the resistance profile of C. glabrata mature biofilms, C. glabrata 
mnn2 was evaluated. Biofilm cell walls were analysed by confocal laser scanning microscopy 
(CLSM) and their susceptibility was assessed for fluconazole, amphotericin B, caspofungin, and 
micafungin. Crystal violet and Alcian Blue methods were performed to quantify the biomass and 
the mannans concentration in the biofilm cells and matrices, respectively. The concentration of β-
1,3 glucans was also measured. No visible differences were detected among cell walls of the strains, 
but the mutant had a high biomass reduction, after a drug stress. When compared with the reference 
strain, it was detected a decrease in the susceptibility of the biofilm cells and an increase of β-1,3 
glucans in the C. glabrata mnn2. The deletion of the MNN2 gene in C. glabrata induces biofilm matrix 
and cell wall variabilities that increase the resistance to the antifungal drug treatments. The rise of 
β-1,3 glucans appears to have a role in this effect. 
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1. Introduction 
In opposition to Candida albicans and other Candida species, Candida glabrata grows only as 
blastoconidia, and has a haploid genome [1]. Despite being a part of the natural human microflora, 
under circumstances where the host immune system becomes severely compromised (e.g., 
chemotherapy, traumas), C. glabrata can invade epithelial cells, disseminating via the bloodstream, 
causing systemic diseases [1,2]. In fact, fungal diseases associated with non-Candida albicans Candida 
(NCAC) species have been globally increasing [3,4]. The frequency rates of candidemia attributed to 
C. glabrata are about 15% of all Candida species-related systemic bloodstream infections [5,6], which 
is particularly relevant since, compared with other Candida species infections, the mortality rate 
associated with C. glabrata is the highest (30%) [1,7]. As a matter of fact, the biofilm formation is a 
very important virulence factor for C. glabrata, allowing the yeasts to adhere to biotic and abiotic 
surfaces, developing into organized communities that are extremely refractory to antifungal 
treatment and environmental conditions [8]. 
The yeast cell wall is a dynamic structural organelle crucial for protection against hostile 
environments, maintaining cell shape, assisting adherence to host surfaces, and having a 
fundamental role for fungus-host interactions and immune recognition [2,9]. Per se, it is very likely 
to play an important part in mediating several interactions and hence virulence [9]. The cell wall is 
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comprised of an internal central core of β-1,3 glucans and β-1,6 glucans linked to chitin via β-1,4 
glucans, extended throughout the entire depth of the cell wall structure [10,11]. There is also an 
external layer of highly glycosylated mannoproteins [10,12], which play a major role in host 
recognition, adhesion, cell wall integrity, and include up to 40% of the cell wall dry weight [13,14]. 
These proteins are adorned with both N- and O-linked sugars, mainly mannans, and can end in the 
accumulation of up to 200 mannose units [9,15], attached via a phosphodiester linkage 
(phosphomannan) [16]. The number of mannans units and their molecular weights highly fluctuate 
between species [17], which have important consequences for host-fungus interactions [2,9]. 
Structural studies point out that C. glabrata mannan is more closely related to that of Saccharomyces 
cerevisiae than to C. albicans [18]. Even though, the core of the biosynthetic machinery appears to be 
relatively well conserved [9]. The N-linked protein glycosylation occurs in two stages. Concisely, in 
the first, proteins transverse though the endoplasmic reticulum, resulting in the mature N-mannan 
core, Man8GlcNAc2 [19]; in the second, a α-1,6-backbone is attached to a Och1 core and Mnn9 and 
added with side chains consisting of α-1,2-, and α-1,3-mannose residues, with the α-1,2-mannose 
extending out from the backbone [20]. It is recognised that the deletion of ScMNN2 inhibits the 
accumulation of α-1,2-mannose onto the mannan backbone, hence stopping the elaboration of N-
mannan outer chains [21]. In C. albicans, this greatly conditions the growth, cell morphology, and 
immune recognition [20]. Several mannosyltransferases involved in mannan biosynthesis in S. 
cerevisiae, have been identified, and many of these enzymes are conserved in C. albicans and other 
pathogenic fungi. Remarkably, many of these fungal mannosyltransferases are absent from human 
cells, and thus its study shows prospective in the development of novel antifungals and vaccines. Yet, 
this subject is more advanced in S. cerevisiae and C. albicans, but little is known regarding the role in 
the pathogenesis of C. glabrata, especially in biofilms. 
This work aims to evaluate and to understand the responsibility of mannans on the biofilm 
resistance of antifungals in C. glabrata, through the effect of a MNN2 knock out (KO)–a putative 
component of the N-linked glycosylation machinery on matured biofilm cells, on their cell wall and 
after different drug stresses. 
2. Material and Methods 
2.1. Organisms 
Three strains of C. glabrata were used in the course of this study. One reference strain from the 
American Type Culture Collection (C. glabrata ATCC2001) and two strains kindly provided by Dr. 
Ken Haynes from the University of Exeter (United Kingdom) [9]: the C. glabrata mutant with a MNN2 
gene disruption (C. glabrata mnn2) and its parent strain (C. glabrata HT6) (see Table S1 of 
Supplementary Material). The effect of the revertant strain was already stated and reported 
previously by Dr. Ken Haynes lab [9]. 
The identity of all isolates was confirmed using CHROMagar Candida (CHROMagar, Paris, 
France) and by PCR-based sequencing [22]. The PCR products were sequenced using the ABI-PRISM 
Big Dye terminator cycle sequencing kit (Perkin Elmer, Applied Biosystems, Warrington, UK). 
2.2. Growth Conditions 
For each experiment, C. glabrata ATCC2001 and C. glabrata HT6 strains were subcultured on 
Sabouraud dextrose agar (SDA) (Merck, Darmstadt, Germany) and the mutant C. glabrata mnn2 was 
cultured on SD-his, as indicated by West et al. [9], during 24 h at 37 °C. Cells were then inoculated in 
Sabouraud dextrose broth (SDB, Merck) and incubated for 18 h at 37 °C under agitation at 120 rpm. 
After incubation, the cells were harvested by centrifugation at 3000 g for 10 min at 4 °C and washed 
twice with phosphate buffered saline (PBS 0.1M, pH = 7.5). Pellets were then suspended in RPMI-
1640 (Sigma-Aldrich, Roswell Park, St Louis, MO, USA) and the cellular density was adjusted to 1 × 
105 cells/mL, using a Neubauer counting chamber. 
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2.3. Antifungal Drugs 
Fluconazole (Flu), caspofungin (Csf) and micafungin (Mcf) were kindly provided by Pfizer, S.A. 
(New York, USA), MSD (Kenilworth, NJ, USA) and Astellas (Tokyo, Japan) respectively, in its pure 
compound. Amphotericin B (AmB) was purchased in Sigma. Aliquots of 5000 mg/L were prepared 
using dimethyl-sulfoxide (DMSO). The final concentrations used were prepared with RPMI-1640. 
2.4. Biofilm Matrix Structure: Confocal Laser Scanning Microscopy 
Biofilms were formed in 24-well polystyrene microtiter plates (Orange Scientific, Braine-
l'Alleud, Belgium), on plastic highly adhesive round tissue culture coverslips (13 mm diameter, 
Sarstedt, Germany). For this, 1000 µL of yeast cell suspension (1 × 105 cells/mL in RPMI-1640) were 
added to each well and the biofilms performed as described previously [23]. After 24 h, 500 µL of 
RPMI medium was removed and an equal volume of fresh RPMI with or without the antifungal 
agents was added. 
The staining and confocal laser scanning microscopy (CLSM) were performed similarly to a 
method described previously [24]. Biofilms were fixed in 4% (w/v) of paraformaldehyde (Sigma-
Aldrich) followed by 50% (v/v) ethanol for 10 min at room temperature and allowed to air dry. Then, to 
stain the α-mannopyranosyl residues of the glycosylated mannoproteins (that is, mannans) of the cells, 
they were overlayed with 25 µg/mL Concanavalin A-Alexa Fluor 488 conjugate (ThermoFisher 
Scientific, Bartlesville, OK, USA) in the dark for 10 min at room temperature [10,12,25]. For cell nucleus 
detection, the cells were stained with 100 mg/L of 4’,6-diamidino-2-phenylindole (DAPI, ThermoFisher 
Scientific) for 10 min at room temperature. 
After this, the preparation was washed with water and allowed to air dry. Finally, the sample 
was immediately observed using the CLSM (Olympus BX61, Model FluoView 1000, Tokyo, Japan). 
Images were acquired with the program FV10-ASW 4.2 (Olympus) using a magnification of ×100. 
2.5. Biofilm Antifungal Susceptibility Tests 
The antifungal susceptibility tests were performed using the microdilution method, in 
accordance to the European Committee on Antimicrobial Susceptibility Testing guidelines [26,27]. 
The Minimum Biofilm Eradication Concentration (MBECs), that were previously determined for 
C. glabrata ATCC2001 for all drugs (Flu, AmB, Csf, and Mcf) [27,28], was used to evaluate the biofilm 
susceptibility of C. glabrata mnn2 and the parent strain, C. glabrata HT6. For that, standardized cell 
suspensions (200 µL) were placed into selected wells of 96-wells polystyrene microtiter plates 
(Orange Scientific). RPMI-1640 was used without cells, but with antifungal agent, as a negative 
control. As positive control, cell suspensions were tested without antifungal agent. At 24 h, 100 µL of 
RPMI-1640 was removed and an equal volume of fresh RPMI-1640 plus the respective antifungal 
concentration were added (Flu: 1250 mg/L; AmB: 4 mg/L; Csf: 3 mg/L; Mcf: 17 mg/L–2x concentrated). 
The plates were incubated at 37 °C for more 24 h, a total of 48 h, at 120 rpm. The number of cultivable 
cells on biofilms was determined by the enumeration of colony forming units (CFUs). For that, after 
the period of biofilm formation, all medium was aspired and the biofilms washed once with 200 µL 
of PBS to remove non-adherent cells. Then, biofilms were scraped from the wells and the suspensions 
were vigorously vortexed for 2 min to disaggregate cells from the matrix. Serial decimal dilutions in 
PBS were plated on SDA and incubated for 24 h at 37 °C [29]. The results were presented in percentage 
of biofilm cell reduction. 
Total biofilm biomass was quantified by Crystal Violet (CV) staining [28]. After biofilms 
formation, the medium was aspirated and non-adherent cells removed by washing the biofilms with 
sterile ultra-pure water. Then, biofilms were fixed with 200 µL methanol, which was removed after 
15 min of contact. The microtiter plates were allowed to dry at room temperature, and 200 µL of CV 
(1% v/v) were added to each well and incubated for 5 min. Then, wells were gently washed twice 
with sterile, ultra-pure water and 200 µL of acetic acid (33% v/v) were added to release and dissolve 
the stain. The absorbance of the obtained solution was read in a microtiter plate reader (Bio-Tek 
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Synergy HT, Izasa, Lisbon, Portugal) at 570 nm. The results were presented as absorbance per unit 
area (Abs/cm2). 
2.6. Effect of the Antifungals on Biofilm Cells’ Walls and on Biofilm Matrix Composition 
2.6.1. Matrix Extraction Method 
Biofilms were formed as explained above. After 48 h, biofilms were scraped from the 24-well 
plates, resuspended in ultra-pure water, sonicated (Ultrasonic Processor, Cole-Parmer, IL, USA) for 
30 s at 30 W, and then the suspension vortexed for 2 min. The suspension was centrifuged at 5000 g 
for 5 min at 4 °C and the supernatant filtered through a 0.2 µm nitrocellulose filter. The pellets were 
dried at 37 °C until a constant dry biofilm weight was achieved. 
2.6.2. Quantification of Mannans on Biofilm Cells and on Biomass—Quantitative Alcian Blue 
Binding Assay 
Alcian Blue assay was performed according previously described by Odani et al. [30] with slight 
adjustments [24]. Regarding the mannans on cell membranes, biofilms of C. glabrata strains were 
grown as previously described, scraped and sonicated (Ultrasonic Processor) for 30 s at 30 W, and 
then the suspension vortexed for 2 min, to separate cells form the biofilm matrices. Next, the isolated 
cells were washed with deionized water, the OD600 read and adjusted at an OD600 of 0.6 in deionized 
water. Afterwards, the cells were washed with 0.02 N HCl (pH = 3), the pellet was suspended in 1 
mL of 30 µg/mL Alcian blue dye dissolved in 0.02 N HCl (pH = 3) and incubated for 10 min at room 
temperature. Then, the cells were pelleted and evaluated for dye binding. To quantify dye binding 
and dye remaining in the supernatant after binding the stain was measured spectrophotometrically 
at 600 nm. To calculate the Alcian Blue Binding the following equations were used: 
Amount of dye adsorbed to the cells (T): T (µg) = 61.3 x (OD600 ori–OD600 sup) (OD600 ori—OD 
of the Alcian Blue Dye working solution; OD600 sup—OD of the supernatant); 
Alcian Blue Binding (µg/OD600) = (T x d)/OD600 c.c. 
(ODc.c.—the exact OD reading; d—dilution factor). 
2.6.3. Alcian Blue Quantitative Assay on Biofilms 
To measure the relative percentage of mannans on biofilm (total biomass), the medium with 
planktonic cells was all removed from the well and the biofilm was washed with 0.02 N HCl (pH = 
3). Next, the biofilm was scraped, suspended in 1 mL of 30 µg/mL Alcian blue dye dissolved in 0.02 
N HCl (pH = 3), incubated for 10 min at room temperature and pelleted for evaluation of dye binding. 
To calculate relative percentage of mannans on biofilm the following equation was used: 
% mannans on biofilm: [(OD600 ori–OD600 sup)/OD600 ori] × 100  
(OD600 ori—OD of the Alcian Blue Dye working solution; OD600 sup—OD of the supernatant). 
2.6.4. Isolation of Candida glabrata Biofilm Cells Walls. 
Cell wall fractionation was performed as described by Pitarch et al. [31] with slight 
modifications. For that, biofilms were prepared as described above. C. glabrata biofilm cells were 
collected by centrifugation, washed two times with PBS and sonicated at 30 W for 30 s, in order to 
allow separation of the cells from matrix. Next, biofilm cells were separated by centrifugation at 5000 
g for 5 min in a cell wall fraction (pellet) and a soluble cytoplasmic fraction (supernatant). Following 
this, the cell wall fraction was dissolved in 500 µL of buffer with phenylmethylsulfonyl fluoride 
(PMSF) (1 mM) and transferred to “lysis” tube with 500 µL of glass beads for the cells disruption of 
the cells in the FastPrep (MP, Biomedicals, Illkirch-Graffenstaden, France) at maximum speed for 30 
s. The “lysis” tube was placed in a mixture of ice and water for 30 s. These steps were repeated seven 
more times. This procedure was carried out until complete cell breakage, verified beforehand by 
phase-contrast microscopic examinations and a posteriori by the failure of cells to grow on YPD-
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chloramphenicol plates. Then, the samples were transferred to microcentrifuge tubes and spin in 
microfuge centrifuge at 4 °C for 3 min at 2500 g. Hereafter, the isolated cell walls were washed with 
solutions of decreasing concentrations of NaCl (five times with each of the following ice-cold 
solutions: 5% NaCl, 2% NaCl, 1% NaCl, and 1 mM PMSF) to remove any extracellular or cytosolic 
protein contaminants that might be adhered to the cell walls through electrostatic forces. The 
supernatant was transferred to fresh microfuge tubes and centrifuged at 4 °C for 10 min at 10,000 g. 
The supernatants were finally transferred to fresh tubes. 
2.6.5. β-1,3 glucans Concentration Determination 
The β-1,3 glucans concentration was determined using Glucatell kit (Cape Cod, East Falmouth, 
MA, USA). The values were normalized per dry weight of biofilm on biofilm matrices and per pg/mL 
of β-1,3 glucans on biofilm cells. 
2.7. Statistical Analysis 
The experiments were performed in triplicate and in three independent assays. The results were 
compared using one-way analysis of variance (ANOVA), Tukey’s post hoc multiple comparisons 
tests, using GraphPad Prism 7 software (GraphPad Software, San Diego, CA, USA). All tests were 
performed with a confidence level of 95%. 
3. Results 
First, with the purpose of visualizing the effect of the MNN2 gene KO on C. glabrata cell walls, the 
biofilms were observed microscopically by CLSM (Figure 1). The images of the 48-h-biofilms of C. 
glabrata ATCC2001, C. glabrata mnn2, and C. glabrata HT6 showed that the gene deletion, 
apparently, had no effect on the cell wall, since there were no relevant differences among the three 
strains (Figure 1). All strains demonstrated to have good biofilm forming capacity, composed by 
yeasts in a continuous carpet [23,32,33] (Figure 1). Yet and curiously, C. glabrata mnn2 and C. glabrata 
HT6 exhibited higher amount of multilayer structures, whereas C. glabrata ATCC2001 showed a less 
amount of yeast cells forming these structures (Figure 1). 
3.1. Effect of the Antifungals on Biofilms 
The effect of several drugs—Flu, AmB, Csf, and Mcf—was tested on C. glabrata ATCC2001, C. 
glabrata mnn2, and C. glabrata HT6 biofilms. The MBECs for C. glabrata ATCC2001 were determined 
previously [28,29,34] and used as the reference value for the other strains in this study. The results of 
the determination of the total biomass quantification are shown in Figure 2. In general, all strains 
showed a biomass reduction after contact with antifungals, but the response was not linear for the 
three C. glabrata strains. The controls revealed high capacities to produce biofilm, demonstrating that 
the lack of mannans in the mutant did not affect the quantity of biofilm produced. When the drugs 
were added, the mutant strain had a higher biomass loss, when compared with the controls and with 
C. glabrata ATCC2001 and C. glabrata HT6 (Figure 2). 
Table 1 shows the CFU count of the biofilm cells. When in contact with the drugs (MBEC), both 
the mutant and the parent strain were more tolerant to Flu, AmB, Csf, and Mcf, than ATCC2001. 
Interestingly, only AmB was capable of reducing more than 1 Log10 of the initial CFU in the 
mutant strain, evidencing a higher resistance profile, when compared to the wild type strain, in which 
the echinocandins showed to have a good antifungal activity. Results demonstrate that, the initial 
CFU of the biofilm cells were very similar among the strains. It is, thus, probable that the differences 
in the antifungals susceptibilities were related to the biofilm matrices and/or in differences in the cell 
wall composition of each strain. In order to evaluate this, the composition of the cells walls and the 
biofilm matrices were also determined. 
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Figure 1. Confocal laser scanning microscopy image a 48-h-biofilm of Candida glabrata ATCC2001, C. 
glabrata HT6 and C. glabrata mnn2. The biofilm images were acquired using a confocal scanning 
laser microscope (Olympus BX61, Model FluoView 1000). Filters: DAPI (100 mg/L emissions filters 
BA 430–470) and Concanavalin A, Alexa Fluor 488 conjugate (50 mg/L emissions filters BA 505–605). 
Images were acquired with the program FV10-ASW 4.2 (Olympus) using a magnification of 100×. 
Measure bar: 10 µm. 
Table 1. Log10 of CFU/cm2 ± Standard Deviation of biofilm cells using the minimum biofilm 
eradication concentrations (MBECs) of the reference strain (C. glabrata ATCC2001) for Flu, AmB, Csf, 
and Mcf for C. glabrata HT6 and C. glabrata mnn2. 
Strain Control Flu AmB Csf Mcf 
C. glabrata ATCC2001 5.90 ± 0.18 4.95 ± 0.44 4.40 ± 0.30 3.80 ± 1.27 3.40 ± 0.07 
C. glabrata HT6 5.80 ± 0.36 3.69 ± 0.02 4.37 ± 0.45 5.42 ± 0.42 5.53 ± 0.41 
C. glabrata mnn2 6.16 ± 0.31 5.10 ± 0.43 4.23 ± 0.58 5.61 ± 0.11 4.98 ± 0.13 
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Figure 2. Crystal Violet in a 48-h-biofilm of C. glabrata ATCC2001, C. glabrata HT6, and C. glabrata 
mnn2 with and without antifungal agents. The quantification of the biomass is presented by abs/cm2. 
(* p < 0.05; *** p < 0.0005; **** p < 0.0001). Cg: C. glabrata; Flu: fluconazole; AmB: amphotericin B; Csf: 
caspofungin; Mcf: micafungin. 
3.2. Effect of the Antifungals on Biofilm’s Cells Walls and Matrix 
So as to estimate the phosphomannans content in the biofilm cells, the quantitative Alcian Blue 
binding assay was performed (Figure 3). 
 
Figure 3. Alcian Blue binding assay. Data represent the mean amount of dye bound per biofilm cell 
of C. glabrata ATCC2001, C. glabrata HT6, and C. glabrata mnn2 (undetected). (Cg—C. glabrata. * p < 
0.05; ** p < 0.001). 
The results showed that there was an increase in the mannans in the biofilm cells after the contact 
with antifungals drugs in C. glabrata ATCC2001 (Figure 3) and, comparing with the control group, C. 
glabrata HT6 showed to have an increase in mannans only when Flu, AmB, and Mcf was applied to 
the biofilm, but not with Csf. Regarding C. glabrata mnn2, the performance was different. The results 
showed that the KO of MNN2 gene significantly reduced the ability of cells to bind to Alcian Blue, in 
comparison with the other strains, to a point that it could not be quantified (Figure 3). 
In addition, the content in mannans was also quantified on the biofilm matrices, which was, to 
authors’ knowledge, performed here for the first time (Figure 4). 
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Figure 4. Alcian Blue binding assay in biofilm matrices of C. glabrata ATCC2001, C. glabrata HT6, 
and C. glabrata mnn2. Data represent the percentage of mannans on biofilm. (Cg—C. glabrata.). 
In comparison with the controls, the results showed that all strains had less mannans content on 
the matrices in presence of antifungal drugs. Not surprisingly, the mutant had the lower quantity of 
these compounds on its matrices. In average, the controls had 50 to 60% of mannans in the matrices 
compositions, while C. glabrata mnn2 had less than 20% (Figure 4). The percentage decreased to 
about 20% after applying almost all drugs, for C. glabrata ATCC2001 and C. glabrata HT6 and around 
10% for the mutant, except for Csf, in which condition, no mannans were detected (p < 0.0005) (Figure 
4). 
The quantification of the β-1,3 glucans on the biofilm matrices of the three C. glabrata strains 
(Figure 5) showed that, comparing with the controls, the content of β-1,3 glucans increased in the 
matrices of C. glabrata ATCC2001. In the case of C. glabrata HT6, particularly with Flu 1250 mg/L (p 
< 0.0001) and AmB 4 mg/L (p < 0.0001) there was a statistically significant rise in glucans production. 
Regarding C. glabrata mnn2 in contact with AmB 4 mg/L and Mcf 17 mg/L (p < 0.05 and p < 0.001, 
respectively), statistically significant rises were also detected. Curiously, although the mutant 
revealed to have less quantity of total polysaccharides in the biofilm matrix than the reference and 
the parent strain (data not shown), it showed to have the highest quantity of β-1,3 glucans per dry 
weight of biofilm matrix among all strains (7.66 × 105 ± 1.03 × 105), demonstrating a matrix richer in 
glucans’ polymers than the other two strains (Figure 5). 
Afterwards, and in order to verify if the C. glabrata mnn2 initial cells were compensating the 
lack mannans of their cell walls with glucans, it was performed the quantification of β-1,3 glucans of 
the biofilm cells’ walls of the controls of the three strains (Table 2). The results confirmed that the 
content of β-1,3 glucans increased, in the mutant cell walls meaning that they have, indeed, a cell wall 
richer in β-1,3 glucans, when compared with the others (statistically significant). 
Table 2. β-1,3 glucans concentration (pg/mL) on the biofilm cells C. glabrata ATCC2001, C. glabrata 
HT6, and C. glabrata mnn2. (* p < 0.05). 
Strain β-1,3 glucans Biofilm Cells Concentration (pg/mL) ± SD 
C. glabrata ATCC2001 359.00 ± 8.20 
C. glabrata HT6 370.00 ± 5.08 
C. glabrata mnn2 387.00 ± 7.00 (*) 
(SD—standard deviation). 
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Figure 5. β-1,3 glucans concentration (pg/mL) on the biofilm matrices of C. glabrata ATCC2001, C. 
glabrata HT6, and C. glabrata mnn2. The values were normalised per dry weight of biofilm. (Cg—
C. glabrata. * p < 0.05; ** p < 0.001; **** p < 0.0001). 
4. Discussion 
Systemic candidiasis is a worldwide emergent problem [1,35], associated with high mortality 
and high economic costs [33–36]. The fungal cell wall consists of β-1,3 glucans, β-1,4 glucans, β-1,6 
glucans and chitin [10] and a layer of highly glycosylated mannoproteins [10,12,25]. 
Immunologically, these proteins called phosphomannans [16] are mainly organised in mannans, 
having a crucial role in adhesion and host recognition (host-fungus interactions) [9,13,37]. 
The results of the CLSM images (Figure1) revealed that, microscopically among the strains, there 
were no variances on the cell wall, but the total biomass quantification (Figure 2) showed nonlinear 
biomass reduction after contact with antifungals. When compared with the other two strains, C. 
glabrata mnn2 demonstrated a higher biomass loss, which was assumed to be correlated to the KO 
in the MNN2 gene and subsequently, the reduced quantity of mannans in its biofilm matrix (Figure 
2). 
The Alcian Blue is a cationic dye, binding to the negatively charged phosphate group of the 
phosphomannan [2,24,30]. This capacity is used to estimate the cell wall phosphomannan content 
[2,24,30]. The N-linked phosphomannan is attached to the branched mannan through α1,2-mannose 
residues, which extend out from the α1,6-mannose backbone. Consequently, a deletion of any the 
MNN2 family members was expected to disturb the phosphomannan content of the cell wall [2]. C. 
glabrata ATCC2001 increased the quantities of mannans on the cell wall in the presence of drugs 
(Figure 3), which may be a possible adaptation of the cells to the stress caused by the antifungal 
agents. Similar cell walls adjustments during drug pressure have been described extensively as being 
directly responsible for antifungal resistance events[1,38–40]; compared with the control group, the 
parent strain (C. glabrata HT6) increased the mannans content when stressed by Flu, AmB, and Mcf, 
but not by Csf (statistically significant, comparing with the AmB, p < 0.001), which demonstrated the 
intra-strain variability, genotypic and phenotypic alterations and also adaptable drug responses [41,42], 
but can also be a result of the molecular changes between Mcf and Csf. Both drugs have a cyclic 
peptide structure with an N-aryl group but with different patterns of hydroxylations and amino 
groups (R2 to R4). The N-aryl side chain (position R1) plays a critical role in the potency and toxicity 
and is the main point for chemical modification of the echinocandin analogues [43,44]. Csf is more 
hydroxylated and has more amino groups, while Mcf has more aryl groups. The substitution of the 
linoleoyl side chain with aryl side chains of low lipophilicity, nonlinear configuration or chains 
changed with highly polar groups end in loss of antifungal activity, proposing that planar, non-polar 
substitutions are critical for the antifungal activity [43,44]. Mcf molecule presents these modifications 
which are also a probable explanation for the differences found in this and in previous works of our 
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group [29]. C. glabrata mnn2 considerably reduced the ability of cells to bind Alcian Blue (Figure 3), 
which has also been demonstrated on planktonic cells [9], suggesting that MNN2 genes family are 
essential for phosphomannan integration, while deletion of other genes indicated a minor reduction in 
phosphomannan concentration [2,16]. This has been previously revealed for other species [14,16,45]. 
Those results raised the possibility that other polysaccharides’ metabolism (e.g., β-1,3 glucans) could 
be enhanced in the detriment of mannans in the mutant. Concerning the Alcian Blue binding assay 
in the biofilm matrices, all the C. glabrata strains showed to have less mannans on the matrices stressed 
by the presence of antifungal drugs, especially the mutant (Figure 4), which revealed that a poorer 
mannans’ matrix is more fragile, more sensible to environmental stresses and, thus, more susceptible 
to biomass loss (corroborating the biomass results). 
Additionally, the β-1,3 glucans tended to increase their presence in the matrices when the 
biofilms were in contact with the drugs (Figure 5). It appears that, after a stress situation, the 
reduction in mannans, that was observed earlier (Figure 4), matches the β-1,3 glucans increase in C. 
glabrata (Figure 5). Moreover, the controls of the reference and the parent strains had 60% of 
mannans in the matrices compositions, while C. glabrata mnn2 had less than 20%. This reinforces the 
fact that the C. glabrata mnn2 biofilm matrix was mostly constituted by β-glucans, as it was 
determined (Figure 5). The quantification of β-1,3 glucans of the cells walls of the biofilm cells of the 
strains (Table 2) confirmed that the quantity of these biopolymers is variable in the cell walls of C. 
glabrata strains. The mutant displayed a cell wall richer in β-1,3 glucans, when compared with the 
others (statistically significant), which demonstrates higher capacities of compensation mechanisms, 
which, adding to the increase in the β-1,3 glucans content of the matrix, may be responsible for a 
more resistance profile to the drugs (Table 2). 
The strong variability in the biofilm matrices and in the cell walls composition of C. glabrata has 
been formerly stated after any drug pressure, being related to higher pathogenicity and virulence 
states. Though, other factors are related to the biofilm drug resistance and one single feature is not 
able to clarify the complete phenomenon of resistance [23,34,46]. The KO of the MNN2 gene has 
demonstrated to influence the drug response profile of biofilm cells, by inducing key changes in the 
matrices and cell wall’s compositions, validating again the great importance of β-glucans in the 
resistance of C. glabrata biofilms to antifungal drugs. Finally, this work also suggests that the 
identification and blocking of genes directly related to the plasticity of the composition of the matrices 
and cell walls are a good path to the search to new antifungal agents. 
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